◎パレクセルが規制問題処理でアウトソーシングサービスを強化
◎パレクセルが規制問題処理でアウトソーシングサービスを強化
AsiaNet 55811
共同JBN 0160 (2014.2.19)
【ボストン(米マサチューセッツ州)2014年2月19日PRN=共同JBN】
*パレクセル・インターナショナルは、クライアントの価値を高めるため一連の規制情報管理ソリューションを拡大する。
世界をリードするバイオ医薬品サービス企業、パレクセル・インターナショナル(PAREXEL International Corporation、NASDAQ:PRXL)は19日、ライフサイエンス業界向けに規制問題処理アウトソーシングサービスに的を絞った市場優先アプローチ、特に承認後の規制活動を重視して提供するよう考案された新しいサービスラインを開始すると発表した。
同社はこのPAREXEL Regulatory Outsourcing(http://www.parexel.com/solutions/consulting/
regulatory-outsourcing-services)を通じて、クライアントの独自のニーズとビジネス問題に基づくクライアント向けサービスを同社専門知識、運用上のアプローチ、テクノロジーを結合してカスタマイズする。同サービスラインは、同社事業部門パレクセル・コンサルティング(PAREXEL Consulting)内に属する。
パレクセルのマーク・A・ゴールバーグ(医博)社長兼最高執行責任者(COO)は「規制環境は常に変化しているので、製薬企業は効率とコストを念頭に置いて対応することが必要になるという新しい問題に直面している。規制上の専門知識、世界的な運用能力、情報管理技術を考慮した場合、パレクセルはこの種の新サービスを提供するユニークな立場にある。クライアントは今後、信頼できるパートナーに任せて、規制上の大部分の活動を費用対効果のある方法で外注することができるようになる」と語った。
PAREXEL Regulatory Outsourcing Servicesラインの新任責任者であるパレクセルのリック・リーゲル本社副社長は「規制問題のアウトソーシングは、市場でますます重視されるようになっており、さらに多くの企業が規制上のニーズ、特に販売製品の規制維持順守を管理する複雑なタスクを支援するアウトソーシングに依存する。今回のサービス提供はクライアントが感じている新たなプレッシャーに応えるユニークなソリューションとなり、クライアントは規制問題の運用と規制関連業務の分野で一層効率的に処理できるようになる」と語った。
PAREXEL Regulatory Outsourcing Servicesの開始は、パレクセルの規制情報管理ソリューション・ポートフォリオを拡大する。パレクセルは2012年にLIQUENT, Inc.を買収したことによって、堅ろうな情報技術プラットフォームであるLIQUENT InSight(登録商標)を追加することでその規制問題処理能力を強化することになった。
▽パレクセル・インターナショナル(PAREXEL International Corporation)について
パレクセル・インターナショナルは世界をリードするバイオ医薬品サービス企業であり、広い領域で知識ベースの委託研究、コンサルティング、医療コミュニケーション・テクノロジーソリューションを世界の製薬、バイオテクノロジー、医療機器業界に提供している。市場進出時間、ピーク・マーケット・ペネトレーションを促進するソリューションの提供にコミットしているパレクセルは、医薬品開発と規制コンサルティングから臨床薬理学、臨床試験管理(http://www.parexel.com/solutions/informatics/clinical-data-manage)、医療教育、償還までつながる開発と商品化にわたる重要な専門知識を取得している。パレクセルの子会社であるパレクセル・インフォマティクス(PAREXEL Informatics, Inc.)は、臨床開発プロセスに役立つ最先端テクノロジーソリューションを提供する。米マサチューセッツ州ボストン近郊に本社を置くパレクセルは、世界50カ国の76カ所で活動しており、従業員は1万5100人。パレクセル・インターナショナルについての詳しい情報はwww.parexel.comを参照。
PAREXEL、PAREXEL Informatics、LIQUENT、HERON はPAREXEL International Corporationもしくはその子会社の商標あるいは登録商標である
▽問い合わせ先
Diana Martin, Vice President, Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1-617-502-4300
Email: PAREXEL@pancomm.com
ソース:PAREXEL International Corporation
PAREXEL Launches New Regulatory Outsourcing Service Line
PR55811
BOSTON, Feb. 19, 2014 /PRN=KYODO JBN / --
-- Company broadens portfolio of regulatory information management
solutions to enhance client value
PAREXEL International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced the launch of a new
service line designed to provide a focused, market-driven approach to
regulatory outsourcing services in the life sciences industry, with a primary
emphasis on post-approval regulatory activities.
Through PAREXEL Regulatory Outsourcing (
http://www.parexel.com/solutions/consulting/regulatory-outsourcing-services/ )
Services, the Company will customize these services for clients based upon
their unique needs and business challenges by combining expertise, operational
approaches and technology. The service line will reside within the PAREXEL
Consulting business segment.
"With the ever-changing regulatory environment, pharmaceutical companies face
new challenges that need to be addressed with efficiency and cost in mind,"
said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL.
"PAREXEL is uniquely positioned to provide this new service offering, given our
regulatory expertise, global operational capabilities and information
management technology. Clients will now be able to outsource significant
portions of their regulatory activities to a trusted partner in a
cost-effective manner."
"Regulatory outsourcing is growing increasingly important in the market as more
and more companies rely on outsourcing to help them with the complex task of
managing their regulatory needs, especially the regulatory maintenance of their
marketed products," said Rick Riegel, Corporate Vice President and new head of
the PAREXEL Regulatory Outsourcing Services line. "This service offering
provides a unique solution that addresses new pressures felt by our clients,
allowing them to become more efficient in the area of regulatory operations and
affairs."
The launch of PAREXEL Regulatory Outsourcing Services broadens PAREXEL's
portfolio of regulatory information management solutions. In 2012, PAREXEL's
acquisition of LIQUENT, Inc. strengthened its regulatory capabilities by adding
a robust information technology platform, LIQUENT InSight(R).
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite time-to-market and
peak-market penetration, PAREXEL has developed significant expertise across the
development and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials management,
medical education and reimbursement. PAREXEL Informatics, Inc., a subsidiary of
PAREXEL, provides advanced technology solutions to facilitate the clinical
development process. Headquartered near Boston, Massachusetts, PAREXEL operates
in 76 locations in 50 countries around the world, and has 15,100 employees.
For more information about PAREXEL International, visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, LIQUENT, and HERON are registered trademarks of
PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding future results and
events, including, without limitation, statements regarding expected financial
results, future growth and customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the words
"believes," "anticipates," "plans," "expects," "intends," "appears,"
"estimates," "projects," "will," "would," "could," "should," "targets," and
similar expressions are also intended to identify forward-looking statements.
The forward-looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ significantly
from the results discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference include, but are
not limited to, risks associated with: actual operating performance; actual
expense savings and other operating improvements resulting from recent and
anticipated restructurings; the loss, modification, or delay of contracts which
would, among other things, adversely impact the Company's recognition of
revenue included in backlog; the Company's dependence on certain industries and
clients; the Company's ability to win new business, manage growth and costs,
and attract and retain employees; the Company's ability to complete additional
acquisitions, and to integrate newly acquired businesses including the recent
acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of
business; the impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and third parties;
the potential adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and other
risks. Such factors and others are discussed more fully in the section
entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the
fiscal quarter ended December 31, 2013 as filed with the SEC on January 31,
2014, which "Risk Factors" discussion is incorporated by reference in this
press release. The Company specifically disclaims any obligation to update
these forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company's estimates or
views as of any date subsequent to the date of this press release.
Contacts:
Diana Martin, Vice President, Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1-617-502-4300
Email: PAREXEL@pancomm.com
SOURCE: PAREXEL International Corporation
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。